Volume 30, Issue 4 (Avicenna Journal of Clinical Medicine-Winter 2024)
Avicenna J Clin Med 2024, 30(4): 187-193 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nazari A, Karim Ghasemi I, Sayadi A. Efficacy of Isosorbide in Post Extra Corporeal Shock Wake Lithotripsy Stone-Free Time. Avicenna J Clin Med 2024; 30 (4) :187-193
URL: http://sjh.umsha.ac.ir/article-1-2864-en.html
URL: http://sjh.umsha.ac.ir/article-1-2864-en.html
1- Department of Surgery, Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
2- Department of Radiology, Clinical Research Development Unit, Moradi Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
3- Department of Psychiatric Nursing, Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran ,sayadiahmad@yahoo.com
2- Department of Radiology, Clinical Research Development Unit, Moradi Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
3- Department of Psychiatric Nursing, Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran ,
Abstract: (1463 Views)
Background and Objective: Extracorporeal shockwave lithotripsy (ESWL) is mong the the low-risk treatment methods of treating kidney stones. Specialists are looking for ways to remove small stones caused by ESWL in patients as soon as possible. The present study aimed to determine the effect of isosorbide on the duration of renal pelvis excretion after ESWL.
Materials and Methods: In this clinical trial, 176 patients with renal pelvis < 20 mm, who were referred to the ESWL Department of Moradi Hospital, Rafsanjan, Iran, in 2019, were examined. After lithotripsy, the patients were randomly assigned into two intervention groups of receivers of isosorbide 20 mg tablets every 12 hours for two weeks and placebo control for two weeks. The collected data was analyzed using Mann-Whitney and Kruskal-Wallis statistical tests.
Results: The success of ESWL was 78.2% in the isosorbide group and 77.5% in the placebo group (P=0.919). The average duration of stone excretion in the isosorbide group was 4.21 ± 1.05 days, and the placebo group was 4.79 ± 1.16 (P=0.001). In the isosorbide group, the duration of stone excretion in patients with stone size 16-20 mm was less than 16 mm (P=0.011). The average duration of stone excretion in patients 36-55 years old (P=0.021) and patients with right-sided stones (P=0.008) in the isosorbide group was less than the placebo group.
Conclusion: Isosorbide, accompanied by other treatments, reduced the duration of stone excretion after ESWL. Moreover, although Isosorbide can be used to improve the management of patients with kidney stones, more studies are needed to confirm this finding.
Materials and Methods: In this clinical trial, 176 patients with renal pelvis < 20 mm, who were referred to the ESWL Department of Moradi Hospital, Rafsanjan, Iran, in 2019, were examined. After lithotripsy, the patients were randomly assigned into two intervention groups of receivers of isosorbide 20 mg tablets every 12 hours for two weeks and placebo control for two weeks. The collected data was analyzed using Mann-Whitney and Kruskal-Wallis statistical tests.
Results: The success of ESWL was 78.2% in the isosorbide group and 77.5% in the placebo group (P=0.919). The average duration of stone excretion in the isosorbide group was 4.21 ± 1.05 days, and the placebo group was 4.79 ± 1.16 (P=0.001). In the isosorbide group, the duration of stone excretion in patients with stone size 16-20 mm was less than 16 mm (P=0.011). The average duration of stone excretion in patients 36-55 years old (P=0.021) and patients with right-sided stones (P=0.008) in the isosorbide group was less than the placebo group.
Conclusion: Isosorbide, accompanied by other treatments, reduced the duration of stone excretion after ESWL. Moreover, although Isosorbide can be used to improve the management of patients with kidney stones, more studies are needed to confirm this finding.
Extended Abstract [HTML 50 KB] (91 Download)
References
1. Moftakhar L, Jafari F, Ghoddusi Johari M. Prevalence and risk factors of kidney stone disease in population aged 40–70 years old in Kharameh cohort study: a cross-sectional population-based study in southern Iran. BMC Urol. 2022;22(1):205. PMID: 36536352 DOI: 10.1186/s12894-022-01161-x
2. Patti L, Leslie SW. Acute Renal Colic. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023. StatPearls Publishing LLC. 2023. PMID: 28613743
3. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86-96. PMID: 20811557
4. Petrides N, Ismail S, Anjum F, Sriprasad S. How to maximize the efficacy of shockwave lithotripsy. Turk J Urol. 2020;46(1):S19-S26. PMID: 33135997 DOI: 10.5152/tud.2020.20441
5. Desai M, Sun Y, Buchholz N, Fuller A, Matsuda T, Matlaga B, et al. Treatment selection for urolithiasis: percutaneous nephrolithomy, ureteroscopy, shock wave lithotripsy, and active monitoring. World J Urol. 2017;35(9):1395-9. PMID: 28303335 DOI: 10.1007/s00345-017-2030-8
6. Türk C, Neisius A, Petřík A. Urolithiasis - Introduction - Uroweb. 2021.
7. Aboumarzouk OM, Kata SG, Keeley FX, McClinton S, Nabi G. Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi. Cochrane Database Syst Rev. 2012;5:CD006029. PMID: 22592707 DOI: 10.1002/14651858.CD006029
8. Yang C, Li S, Cui Y. Comparison of YAG Laser Lithotripsy and Extracorporeal Shock Wave Lithotripsy in Treatment of Ureteral Calculi: A Meta-Analysis. Urol Int. 2017;98(4):373-81. PMID: 27798945 DOI: 10.1159/000452610
9. Parker-Cohen PD. Extracorporeal shock-wave lithotripsy treatment for kidney stones. Nurse Pract. 1988;13(3):37-42. PMID: 3374867
10. Moxey-Mims MM, Stapleton FB. Hypercalciuria and nephrocalcinosis in children. Curr Opin Pediatr. 1993;5(2):186-90. PMID: 8374638 DOI: 10.1097/00008480-199304000-00009
11. Nazari A, Mokhtaree M, ZareAskari Z. Efficacy of Hydrochlorothiazide in Post Extra Corporeal Shock Wake Lithotripsy Stone-free time in Patients Referred to the ESWL Ward of Moradi Hospital of Rafsanjan. Community Health Journal. 2017;11(4):30-7. DOI: 10.22123/chj.2018.92414.1015
12. Hamidi Madani A, Kazemzadeh M, Pourreza F, Shakiba M, Farzan A, Asadollahzade A, et al. Randomized controlled trial of the efficacy of isosorbide-SR addition to current treatment in medical expulsive therapy for ureteral calculi. Urol Res. 2011;39(5):361-5. PMID: 21207018 DOI: 10.1007/s00240-010-0357-3
13. Hussain Z, Inman RD, Elves AW, Shipstone DP, Ghiblawi S, Coppinger SW. Use of glyceryl trinitrate patches in patients with ureteral stones: a randomized, double-blind, placebo-controlled study. Urology. 2001;58(4):521-5. PMID: 11597530 DOI: 10.1016/s0090-4295(01)01323-1
14. Kekec Z, Yilmaz U, Sozuer E. The effectiveness of tenoxicam vs isosorbide dinitrate plus tenoxicam in the treatment of acute renal colic. BJU Int. 2000;85(7):783-5. PMID: 10792152 DOI: 10.1046/j.1464-410x.2000.00613.x
15. Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology 12/E (LANGE Basic Science). 12th ed. New york: McGraw-Hill Medical. 2012.
16. Raynal G, Bellan J, Saint F, Tillou X, Petit J. Ureter drugs. Progres en urologie. journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2008;18(3):152-9. DOI: 10.1016/j.purol.2008.02.001
17. Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh Urology. 11 ed. New York: Elsevier. 2015.
18. Lai HC, Lin HJ, Huang ST. Chinese herbal medicine to treat urolithiasis in a patient with right flank pain and hematuria: A case report. Complement Ther Med. 2018;36:118-22. PMID: 29458917 DOI: 10.1016/j.ctim.2017.12.007
19. Davenport K, Timoney AG, Keeley FX. Conventional and alternative methods for providing analgesia in renal colic. BJU Int. 2005;95(3):297–300. PMID: 15679781 DOI: 10.1111/j.1464-410X.2005.05286.x
20. Roshani A, Khosropanah I, Salehi M, Noshad Kamran A. Effects of Isosorbide Dinitrate on the Urinary Flow Rate in Patients With Benign Prostatic Hyperplasia. Urol J. 2010;7(3):183-7. PMID: 20845295
21. Tadayyon F, Izadpanahi M, Aali S, Mazdak H, Khorrami MH. The effect of sublingual isosorbide dinitrate on acute urinary retention due to benign prostatic hyperplasia. Saudi J Kidney Dis Transpl. 2012;23(4):782-5. PMID: 22805391 DOI: 10.4103/1319-2442.98160
22. . Tarhan F, Çelik O, Tosun Ç, Faydacı G, Eryıldırım B. Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial. Urol Int. 2014;93(1):17-21. PMID: 24643055 DOI: 10.1159/000357034
23. Davenport K, Timoney AG, Keeley FX. Conventional and alternative methods for providing analgesia in renal colic. BJU Int. 2005;95(3):297-300. PMID: 15679781 DOI: 10.1111/j.1464-410X.2005.05286.x.
24. Piknova B, Woessner MN, de Zevallos JO, Kraus WE, VanBruggen MD, Schechter AN, et al. Human skeletal muscle nitrate and nitrite in individuals with peripheral arterial disease: Effect of inorganic nitrate supple-mentation and exercise. Physiol Rep. 2022;10(23):e15531. PMID: 36461652 DOI: 10.14814/phy2.15531
25. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396(10243):27-38. PMID: 32479829 DOI: 10.1016/S0140-6736(20)31182-X
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences
Published by UMSHA Press
Journal Tel: +988138380924
Publisher Tel:+988138380548
Website: http://sjh.umsha.ac.ir
Email: s_ journal[at]umsha.ac.ir
